News summarySEC EDGARNov 10, 2026, 12:00 PM
Capricor Therapeutics, 8-K (2.02, 9.01): reported results of operations
Capricor reported third-quarter 2026 results, said its Deramiocel DMD application remains under FDA review with a November 22, 2026 target date, highlighted 76% slower upper-limb decline after placebo patients switched to treatment, and reported approximately $199 million in cash and securities.